Aliases & Classifications for Dry Eye Syndrome

MalaCards integrated aliases for Dry Eye Syndrome:

Name: Dry Eye Syndrome 12 15
Dry Eye Syndromes 55 44 73
Tear Film Insufficiency 12
Xerophthalmia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10140
ICD10 33 H04.12
MeSH 44 D015352
NCIt 50 C34553
UMLS 73 C0013238

Summaries for Dry Eye Syndrome

MalaCards based summary : Dry Eye Syndrome, also known as dry eye syndromes, is related to keratoconjunctivitis sicca and sjogren syndrome, and has symptoms including dryness of eye and dacryops. An important gene associated with Dry Eye Syndrome is AQP5 (Aquaporin 5), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Miconazole and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and thyroid, and related phenotype is vision/eye.

Wikipedia : 76 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Dry Eye Syndrome

Diseases related to Dry Eye Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 33.1 IL6 LTF NGF TNF
2 sjogren syndrome 11.4
3 scorpion envenomation 10.9 IL6 TNF
4 premature ovarian failure 1 10.8
5 leukomalacia 10.8 IL6 TNF
6 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL6 TNF
7 perinatal necrotizing enterocolitis 10.7 EGF IL6 TNF
8 streptococcal toxic-shock syndrome 10.6 IL6 TNF
9 burning mouth syndrome 10.6 IL6 NGF TNF
10 laryngitis 10.6 FGF2 IL6 TNF
11 interstitial cystitis 10.6 EGF IL6 NGF
12 rheumatoid lung disease 10.6 MUC1 TNF
13 gingivitis 10.6 IL6 LTF TNF
14 critical limb ischemia 10.6 HGF IL6 TNF
15 radiation proctitis 10.6 FGF2 LTF TNF
16 spinal cord injury 10.6 ARG1 IL6 TNF
17 proctitis 10.5 FGF2 LTF TNF
18 obstructive jaundice 10.5 HGF IL6 TNF
19 rasmussen encephalitis 10.5 BMP6 IL6 TNF
20 stromal keratitis 10.5 IL6 LCN1 TNF
21 gastric ulcer 10.5 EGF FGF2 HGF
22 gastrointestinal system disease 10.4 IL6 LTF TNF
23 null-cell leukemia 10.4 IL6 TNF
24 breast mucoepidermoid carcinoma 10.4 MUC1 MUC5AC
25 cystitis 10.4 EGF IL6 NGF TNF
26 interstitial lung disease 10.4 IL6 MUC1 TNF
27 familial progressive hyperpigmentation 10.3 FGF7 HGF
28 fasciitis 10.3 BMP6 IL6 MUC1 TNF
29 limb ischemia 10.3 FGF2 HGF IL6 TNF
30 central nervous system disease 10.3 IL6 NGF TNF
31 respiratory system disease 10.2 IL6 MUC5AC TNF
32 otitis media 10.2 IL6 MUC5AC TNF
33 anthracosis 10.2 BMP6 TNF
34 aging 10.1
35 rheumatoid arthritis 10.0
36 arthritis 10.0
37 cataract 10.0
38 allergic conjunctivitis 10.0
39 conjunctivitis 10.0
40 vascular disease 10.0 BMP6 FGF2 IL6 TNF
41 graft-versus-host disease 10.0
42 depression 10.0
43 hematopoietic stem cell transplantation 9.9
44 thyroiditis 9.9
45 chronic graft versus host disease 9.9
46 cap polyposis 9.7 MUC4 MUC5AC
47 systemic lupus erythematosus 9.7
48 macular degeneration, age-related, 1 9.7
49 anxiety 9.7
50 microvascular complications of diabetes 5 9.7

Graphical network of the top 20 diseases related to Dry Eye Syndrome:



Diseases related to Dry Eye Syndrome

Symptoms & Phenotypes for Dry Eye Syndrome

UMLS symptoms related to Dry Eye Syndrome:


dryness of eye, dacryops

MGI Mouse Phenotypes related to Dry Eye Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.23 AQP5 EGF FGF2 FGF7 IL6 MUC5AC

Drugs & Therapeutics for Dry Eye Syndrome

Drugs for Dry Eye Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90-82-4 7028
7
Travoprost Approved Phase 4 157283-68-6 5282226
8
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
11
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
12
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
13
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
14
Loteprednol Approved Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
15
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
16
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
17
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 83-43-2 6741
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-24-8 5755
22
Azithromycin Approved Phase 4 83905-01-5 55185 447043
23
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
24
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
25
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
26
Latanoprost Approved, Investigational Phase 4,Phase 3,Not Applicable 130209-82-4 5282380 5311221
27
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
28
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
29
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
30
Sulfacetamide Approved Phase 4 144-80-9 5320
31
Tobramycin Approved, Investigational Phase 4,Phase 1,Not Applicable 32986-56-4 5496 36294
32
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
33
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
34
Doxazosin Approved Phase 4 74191-85-8 3157
35
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
36
Oxybutynin Approved, Investigational Phase 4,Not Applicable 5633-20-5 4634
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
38
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
39
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
40
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
41
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
42
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
43
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Not Applicable 1406-66-2 14986
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
46
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 6221 5280795
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
48
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
49
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
50
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795

Interventional clinical trials:

(show top 50) (show all 798)
# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
4 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
8 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
9 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
10 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
11 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
12 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
13 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
14 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
15 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
16 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
17 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
18 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
19 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
20 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
21 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
22 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
23 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
24 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
25 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
26 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
27 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
28 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
29 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
30 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
31 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
32 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
33 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
34 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
35 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
36 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
37 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
38 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
39 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
40 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
41 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
42 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
43 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
44 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
45 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
46 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
47 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
48 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
49 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optive™);Lubricating Eye Drops (blink® Tears)
50 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate

Search NIH Clinical Center for Dry Eye Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dry eye syndromes

Genetic Tests for Dry Eye Syndrome

Anatomical Context for Dry Eye Syndrome

MalaCards organs/tissues related to Dry Eye Syndrome:

41
Eye, Salivary Gland, Thyroid, Testes, Bone, B Cells, Bone Marrow

Publications for Dry Eye Syndrome

Articles related to Dry Eye Syndrome:

(show top 50) (show all 283)
# Title Authors Year
1
Outcomes of Thermal Pulsation Treatment for Dry Eye Syndrome in Patients With Sjogren Disease. ( 29708939 )
2018
2
Feline dry eye syndrome of presumed neurogenic origin: a case report. ( 29318025 )
2018
3
Optimizing acupuncture treatment for dry eye syndrome: a systematic review. ( 29724255 )
2018
4
Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome. ( 29068175 )
2018
5
Dry eye syndrome: developments and lifitegrast in perspective. ( 29391773 )
2018
6
Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. ( 29527528 )
2018
7
The Correlation between Daily Lens Wear Duration and Dry Eye Syndrome. ( 29875854 )
2018
8
Dry Eye Syndrome in Intensive Care Units: a concept analysis. ( 29924155 )
2018
9
Magnitude of diabetes and hypertension among patients with Dry Eye Syndrome at a tertiary hospital of Riyadh, Saudi Arabia - A case series. ( 28559720 )
2017
10
Autologous artificial tears used for treatment of dry eye syndrome in patients with chronic graft versus host disease. ( 29162791 )
2017
11
Aqueous Deficient Dry Eye Syndrome Post Orbital Radiotherapy: A 10-Year Retrospective Study. ( 28660094 )
2017
12
Protective effects of carbenoxolone, an 11I^-HSD1 inhibitor, against chemical induced dry eye syndrome. ( 28887719 )
2017
13
Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. ( 28827614 )
2017
14
Dry Eye Syndrome ( 29262012 )
2017
15
Punctal occlusion for dry eye syndrome. ( 28649802 )
2017
16
Epigallocatechin Gallate-Loaded Gelatin-g-Poly(N-Isopropylacrylamide) as a New Ophthalmic Pharmaceutical Formulation for Topical Use in the Treatment of Dry Eye Syndrome. ( 28839279 )
2017
17
Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial. ( 28367524 )
2017
18
Fingerprick autologous blood: a novel treatment for dry eye syndrome. ( 28622325 )
2017
19
Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. ( 28771187 )
2017
20
Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome. ( 29158874 )
2017
21
Efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids in dry eye syndrome: a systematic review of randomized clinical trials. ( 28371493 )
2017
22
Aging eye microbiota in Dry Eye Syndrome in patients treated with Enterococcus faecium and Saccharomyces boulardii. ( 28676009 )
2017
23
Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study. ( 28752695 )
2017
24
The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. ( 28910552 )
2017
25
Dry Eye Syndrome in Menopause and Perimenopausal Age Group. ( 28706404 )
2017
26
Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome. ( 28487505 )
2017
27
Tear Fluid Protein Changes in Dry Eye Syndrome Associated with Rheumatoid Arthritis: A Proteomic Approach. ( 27789276 )
2017
28
Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome. ( 28759302 )
2017
29
A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers. ( 29123104 )
2017
30
Evaluation of Decellularized Porcine Jejunum as a Matrix for Lacrimal Gland Reconstruction In Vitro for Treatment of Dry Eye Syndrome. ( 29079859 )
2017
31
Therapeutic inhibitors for the treatment of dry eye syndrome. ( 29115899 )
2017
32
Risk of dry eye syndrome in patients treated with whole-brain radiotherapy. ( 28784430 )
2017
33
Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome. ( 28643798 )
2017
34
Dry Eye Syndrome After Proton Therapy of Ocular Melanomas. ( 28586953 )
2017
35
A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome. ( 28441068 )
2017
36
Automated Measurement of Tear Film Dynamics and Lipid Layer Thickness for Assessment of Non-SjAPgren Dry Eye Syndrome With Meibomian Gland Dysfunction. ( 28060064 )
2017
37
Over the counter (OTC) artificial tear drops for dry eye syndrome. ( 26905373 )
2016
38
Efficacy of Several Therapeutic Agents in a Murine Model of Dry Eye Syndrome. ( 27053565 )
2016
39
Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. ( 26818750 )
2016
40
Analysis of Factors Associated With the Tear Film Lipid Layer Thickness in Normal Eyes and Patients With Dry Eye Syndrome. ( 27537256 )
2016
41
Dry Eye Syndrome Risks in Patients With Fibromyalgia: A National Retrospective Cohort Study. ( 26825913 )
2016
42
Efficacy of a New Ocular Surface Modulator in Restoring Epithelial Changes in an In Vitro Model of Dry Eye Syndrome. ( 27163340 )
2016
43
A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. ( 27445067 )
2016
44
Vitamin D Supplementation for Patients with Dry Eye Syndrome Refractory to Conventional Treatment. ( 27698364 )
2016
45
A Comprehensive Review of Sex Disparities in Symptoms, Pathophysiology, and Epidemiology of Dry Eye Syndrome. ( 27101252 )
2016
46
Cryopreservation and hypothermic storage of lacrimal gland: towards enabling delivery of regenerative medicine therapies for treatment of dry eye syndrome. ( 27976538 )
2016
47
Proper balance of omega-3 and omega-6 fatty acid supplements with topical cyclosporine attenuated contact lens-related dry eye syndrome. ( 27766505 )
2016
48
Serum 25-Hydroxyvitamin D Levels and Dry Eye Syndrome: Differential Effects of Vitamin D on Ocular Diseases. ( 26894581 )
2016
49
The Association between Symptoms of Dry Eye Syndrome and Metabolic Outcome in a General Population in Korea. ( 27366012 )
2016
50
Understanding Symptoms and Quality of Life inA Patients With Dry Eye Syndrome. ( 27224876 )
2016

Variations for Dry Eye Syndrome

Expression for Dry Eye Syndrome

Search GEO for disease gene expression data for Dry Eye Syndrome.

Pathways for Dry Eye Syndrome

Pathways related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 ARG1 EGF FGF2 FGF7 HGF IL6
2
Show member pathways
13.41 BMP6 EGF FGF2 FGF7 HGF IL6
3
Show member pathways
13.3 BMP6 EGF FGF2 FGF7 HGF IL6
4
Show member pathways
13.27 EGF FGF2 FGF7 HGF IL6 MUC1
5
Show member pathways
13.22 BMP6 EGF FGF2 FGF7 HGF IL6
6
Show member pathways
13.18 BMP6 EGF FGF2 FGF7 HGF IL6
7
Show member pathways
13.02 AQP5 BMP6 EGF FGF2 FGF7 HGF
8
Show member pathways
12.93 BMP6 EGF FGF2 FGF7 HGF IL6
9
Show member pathways
12.88 BMP6 EGF FGF2 FGF7 HGF IL6
10
Show member pathways
12.8 EGF FGF2 FGF7 HGF IL6 NGF
11 12.74 EGF FGF2 FGF7 HGF IL6
12
Show member pathways
12.67 EGF FGF2 FGF7 HGF IL6
13
Show member pathways
12.63 EGF FGF2 FGF7 HGF NGF
14 12.62 EGF FGF2 FGF7 HGF NGF TNF
15
Show member pathways
12.18 BMP6 EGF FGF2 FGF7 HGF IL6
16 11.89 EGF FGF2 FGF7 HGF IL6
17
Show member pathways
11.85 MUC1 MUC4 MUC5AC
18 11.79 ARG1 IL6 TNF
19 11.71 FGF2 HGF IL6 MUC1 TNF
20
Show member pathways
11.71 BMP6 EGF FGF2 FGF7 HGF IL6
21 11.69 EGF FGF2 NGF
22 11.47 FGF7 IL6 TNF
23 11.44 HGF IL6 TNF
24 11.39 EGF FGF2 HGF IL6
25 11.36 EGF FGF2 FGF7
26 11.31 AQP5 EGF HGF
27 10.9 EGF FGF2 FGF7 HGF IL6 TNF

GO Terms for Dry Eye Syndrome

Cellular components related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 ARG1 BMP6 EGF FGF2 FGF7 HGF
2 extracellular space GO:0005615 9.53 ARG1 BMP6 EGF FGF2 HGF IL6
3 platelet alpha granule lumen GO:0031093 9.5 EGF HGF ORM1
4 Golgi lumen GO:0005796 9.46 MUC1 MUC4 MUC5AC NGF
5 specific granule lumen GO:0035580 9.43 ARG1 LTF ORM1

Biological processes related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.88 FGF2 HGF IL6 MUC1 TNF
2 peptidyl-tyrosine phosphorylation GO:0018108 9.84 EGF FGF2 FGF7 HGF
3 MAPK cascade GO:0000165 9.83 EGF FGF2 FGF7 HGF TNF
4 positive regulation of endothelial cell proliferation GO:0001938 9.77 ARG1 BMP6 FGF2
5 response to glucocorticoid GO:0051384 9.76 BMP6 IL6 TNF
6 activation of MAPK activity GO:0000187 9.76 EGF FGF2 HGF TNF
7 O-glycan processing GO:0016266 9.75 MUC1 MUC4 MUC5AC
8 positive regulation of MAP kinase activity GO:0043406 9.74 EGF FGF2 TNF
9 positive regulation of epithelial cell proliferation GO:0050679 9.73 BMP6 FGF7 LACRT
10 humoral immune response GO:0006959 9.72 IL6 LTF TNF
11 positive regulation of protein kinase B signaling GO:0051897 9.72 EGF FGF2 FGF7 HGF TNF
12 positive regulation of cell proliferation GO:0008284 9.7 BMP6 EGF FGF2 FGF7 HGF IL6
13 retina homeostasis GO:0001895 9.69 LCN1 LTF PRR4
14 positive chemotaxis GO:0050918 9.67 FGF2 FGF7 HGF
15 phosphatidylinositol phosphorylation GO:0046854 9.67 EGF FGF2 FGF7 HGF
16 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.61 LACRT TNF
17 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.61 LACRT LTF
18 negative regulation of lipid storage GO:0010888 9.6 IL6 TNF
19 negative regulation of interleukin-6 production GO:0032715 9.58 HGF ORM1 TNF
20 positive regulation of osteoblast differentiation GO:0045669 9.56 BMP6 HGF IL6 LTF
21 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.52 FGF7 HGF
22 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.35 EGF FGF7 HGF IL6 LACRT
23 regulation of signaling receptor activity GO:0010469 9.23 BMP6 FGF2 FGF7 HGF IL6 LACRT
24 positive regulation of transcription, DNA-templated GO:0045893 10.02 EGF FGF2 FGF7 IL6 TNF
25 negative regulation of apoptotic process GO:0043066 10.02 HGF IL6 LACRT LTF NGF

Molecular functions related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 BMP6 FGF2 IL6 TNF
2 protein tyrosine kinase activity GO:0004713 9.62 EGF FGF2 FGF7 HGF
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.46 EGF FGF2 FGF7 HGF
4 chemoattractant activity GO:0042056 9.43 FGF2 FGF7 HGF
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGF FGF2 FGF7 HGF
6 growth factor activity GO:0008083 9.23 BMP6 EGF FGF2 FGF7 HGF IL6

Sources for Dry Eye Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....